A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK8245-005 AM2)

• Status: Terminated
• Trial end date: 2009-08-01
• Target enrollment: 0
• Participant gender: All

Summary

A study to assess the safety and efficacy of MK8245 as monotherapy compared to placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• Have Type 2 Diabetes Mellitus

• 18 to 65 years of age

Exclusion Criteria:

• History of Type 1 Diabetes or ketoacidosis

• Have been treated with lipid lowering medications 4 weeks before starting the study

• Have started on a weight loss program and not in the maintenance phase or have started weight loss medication within the last 12 weeks

• Have had surgery in the last 30 days

• History of active liver disease

• History of coronary heart disease or congestive heart failure

• Have had a stroke or transient ischemic neurological disorder in the past 6 months

• Are Human Immunodeficiency Virus (HIV) Positive